Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark

Report Examines ADAP Waiting Lists, Factors Contributing To Cost-Containment Measures
"ADAP Watch," National Alliance of State and Territorial AIDS Directors: The report found that as of May 20, 2009, there were 99 people on AIDS Drug Assistance Program (ADAP) waiting lists in Indiana, Montana, Nebraska and Wyoming -- 37 more people than the previous ADAP Watch report, published in March 2009. The report also found that 11 ADAPs anticipate implementing new cost-containment measures by the end of March 2010, six of which anticipate implementing a waiting list. In addition, the report identifies factors contributing to the need for cost-containment measures, and discusses how state budget deficits are affecting HIV programs, including ADAPs ("ADAP Watch," NASTAD, 6/4).
generic viagra online
Schering-Plough Expands Vicriviroc Phase II Study In Treatment-Naive Patients With HIV
Schering-Plough Corporation (NYSE: SGP) announced that it has extended to stage two an ongoing Phase II clinical study with vicriviroc, its investigational CCR5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected patients with R5-type virus only. In this study, vicriviroc is being evaluated in a novel nucleoside-sparing regimen that is designed to provide additional options for treatment-naive patients in a once daily regimen, while preserving other drug classes for subsequent lines of treatment.
News of the day
In The Case Of Epilepsy, Generic Drugs And Random Product Substitution Are Not Always "Good Medicine"
A recent report released by Wolters Kluwer Health predicts that by the end of the year, nearly two-thirds of all drug prescriptions will be filled with generic drugs. This march to generics is fueled by several factors, which include the current economy, ever-increasing co-payment requirements for brand name drugs and pharmacies" desire to increase their profits by filling prescriptions with high margin generics versus lower margin brand name medicines.
Nutrition

Protecting Kidney Function During Heart Failure

Mayo Clinic cardiology researchers have found a peptide that helps preserve and improve kidney function during heart failure, without affecting blood pressure. Earlier variations of this peptide caused blood pressure to drop limiting the potential benefits to the kidneys. The findings appear in the current Proceedings of the National Academy of Sciences. "Heart failure itself and some of the approaches used to treat it can have detrimental effects on the kidneys," says Mayo cardiologist and lead researcher Robert Simari, M.D. "Our hope is that this compound will help protect kidney function while you"re being treated, and possibly shorten your hospital stay and keep you out of the hospital." This new peptide (a unique link of amino acids) has been tested in the laboratory and in animal models and is expected to move into clinical trials next year. "One of the biggest additional concerns for patients with heart failure is the health of their kidneys," says Dr. Simari. "The extreme case is that it can lead to the kidneys shutting down completely." Nearly 5 million Americans are living with heart failure, a condition where the heart can"t pump enough blood to meet the body"s needs. Symptoms include shortness of breath, exercise intolerance and fluid retention. All can occur when heart function is impaired. Seven Years of Research The mapping of the human genome (2000-2003) revealed a gene that produces a protein called BNP (B-type natriuretic peptide). BNP was not only useful in diagnosing heart problems, it also proved therapeutic in treating heart failure. Unfortunately, says Dr. Simari, it had limited use because many heart failure patients experience low blood pressure and BNP lowered it further. The Mayo investigators discovered an alternative splicing (AS) of BNP in messenger RNA (produced by the same gene). When they shortened the amino acid sequence of ASBNP for testing, they found that it had the same therapeutic benefits as BNP, but without the side effects to blood pressure. Positive impacts include increasing the kidney filtration rate, suppressing harmful protein production, and keeping water and salt flowing from the body. Potentially, this new drug would be given by IV to patients who are being treated in the hospital. "There"s an important reduction of kidney function every time one of these acute heart failure episodes happens," says Dr. Simari. "And by stopping one or more of those decrements, we hope there will be an overall improvement in long-term maintenance of kidney function." Others on the team include Shuchong Pan, M.D., Ph.D., Horng Chen, M.D., Guido Boerrigter, M.D., Candace Lee, Laurel Kleppe, Amir Lerman, M.D., Margaret Redfield, M.D., John Burnett, Jr., M.D., all from Mayo Clinic, and Deborah Dickey, Ph.D., Jennifer Hall, Ph.D., and Lincoln Potter, Ph.D., all from the University of Minnesota. The research was funded by Mayo Clinic, the National Institutes of Health, and Anexon, Inc. Mayo Clinic and five of the investigators associated with this research have a financial interest in the technology studied in the research. In accordance with the Bayh-Dole Act, that technology has been licensed to Anexon. Mayo Clinic and Drs. R. Simari and Dr. S. Pan have received royalties from the licensing of that technology of greater than the federal threshold for significant financial interest. Drs. J.Burnett, M.Redfield and H.Chen have received royalties less than the federal threshold for significant financial interest. In addition, Mayo Clinic holds an equity position in Anexon. Mayo Clinic


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009